点燃 发表于 2025-3-23 11:27:23

Submitted on: 21 May 2012.
Revised on: 23 August 2012.
Accepted on: 14 October 2012.

___________________CANCER CHEMOTHERAPY AND PHARMACOLOGY

PAD416 发表于 2025-3-23 13:51:11

Submitted on: 12 August 2020.
Revised on: 24 October 2020.
Accepted on: 15 November 2020.

___________________CANCER CHEMOTHERAPY AND PHARMACOLOGY

covert 发表于 2025-3-23 21:22:05

Submitted on: 29 May 2011.
Revised on: 09 August 2011.
Accepted on: 09 September 2011.

___________________CANCER CHEMOTHERAPY AND PHARMACOLOGY

检查 发表于 2025-3-23 22:47:40

Submitted on: 03 April 2018.
Revised on: 26 April 2018.
Accepted on: 09 June 2018.

___________________CANCER CHEMOTHERAPY AND PHARMACOLOGY

exacerbate 发表于 2025-3-24 05:47:23

Submitted on: 06 October 2009.
Revised on: 11 January 2010.
Accepted on: 26 February 2010.

___________________CANCER CHEMOTHERAPY AND PHARMACOLOGY

开始从未 发表于 2025-3-24 09:37:15

Submitted on: 22 December 2015.
Revised on: 26 January 2016.
Accepted on: 17 March 2016.

___________________CANCER CHEMOTHERAPY AND PHARMACOLOGY

Subjugate 发表于 2025-3-24 14:08:44

http://reply.papertrans.cn/1/47/4675/4675-17.png

消毒 发表于 2025-3-24 15:09:25

http://reply.papertrans.cn/1/47/4675/4675-18.png

细微的差异 发表于 2025-3-24 19:29:15

Submitted on: 25 January 2008.
Revised on: 19 April 2008.
Accepted on: 04 June 2008.

___________________CANCER CHEMOTHERAPY AND PHARMACOLOGY

PON 发表于 2025-3-25 00:09:51

Submitted on: 04 May 2005.
Revised on: 20 July 2005.
Accepted on: 03 August 2005.

___________________CANCER CHEMOTHERAPY AND PHARMACOLOGY
页: 1 [2] 3 4
查看完整版本: SCIE期刊CANCER CHEMOTHERAPY AND PHARMACOLOGY 2024/2025影响因子:2.771 (CANCER CHEMOTH PHARM) (0344-5704). (PHARMACOLOGY & PHAR